Teva Pharmaceutical Industries Ltd

Contributing Author

Recent Articles by Teva Pharmaceutical Industries Ltd

5 hours	Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November TEVA GlobeNewswire
Oct-20	Teva and Prestige Biopharma Enter License Agreement for Tuznue Commercialization in Europe TEVA GlobeNewswire
Oct-10	FDA Approves Expanded Indication for UZEDY (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder TEVA GlobeNewswire
Sep-25	Teva Releases Q3 2025 Aide Memoire TEVA GlobeNewswire
Sep-25	Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025 TEVA GlobeNewswire
Sep-20	Patients Taking AUSTEDO XR (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction TEVA GlobeNewswire
Sep-20	New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed TEVA GlobeNewswire
Sep-16	Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-'749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting TEVA GlobeNewswire
Sep-09	Teva's Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy TEVA GlobeNewswire
Sep-02	Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September TEVA GlobeNewswire
Aug-28	Teva Announces FDA Approval and Launch of Generic Saxenda (liraglutide injection) - First Generic GLP-1 Indicated for Weight Loss TEVA GlobeNewswire
Aug-06	FDA Approves Expanded Indication for AJOVY (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine TEVA GlobeNewswire
Jul-30	Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components TEVA GlobeNewswire
Jun-26	Teva Releases Q2 2025 Aide Memoire TEVA GlobeNewswire
Jun-25	Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025 TEVA GlobeNewswire
Jun-23	Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY (fremanezumab) for the Prevention of Chronic and Episodic Migraine TEVA GlobeNewswire
Jun-16	Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology TEVA GlobeNewswire
Jun-03	Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer TEVA GlobeNewswire
Jun-03	Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement TEVA GlobeNewswire
May-30	New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025 TEVA GlobeNewswire
May-30	Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date TEVA GlobeNewswire
May-29	Teva Reaffirms "Pivot to Growth" Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day TEVA GlobeNewswire
May-27	Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA TEVA GlobeNewswire
May-27	Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June TEVA GlobeNewswire
May-27	Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma TEVA GlobeNewswire
May-22	Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes TEVA GlobeNewswire
May-20	Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt TEVA GlobeNewswire
May-20	Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy TEVA GlobeNewswire
May-19	Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031 TEVA GlobeNewswire
May-19	Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes TEVA GlobeNewswire
May-15	Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy TEVA GlobeNewswire
May-12	Teva's 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy TEVA GlobeNewswire
May-07	Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City TEVA GlobeNewswire
May-07	Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved TEVA GlobeNewswire
May-05	Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI (ustekinumab-aekn) with Stelara (ustekinumab) TEVA GlobeNewswire

Teva Pharmaceutical Industries Ltd

Recent Articles by Teva Pharmaceutical Industries Ltd

Upgrade your FINVIZ experience